Key Takeaways
- Eli Lilly reports that Foundayo demonstrates superior performance compared to Novo Nordisk’s oral Ozempic in type 2 diabetes treatment.
- The 17.2 mg dose of Foundayo achieved approximately 2% greater weight reduction than the 25 mg oral Ozempic formulation.
- The high-dose oral Ozempic formulation from Novo currently lacks FDA authorization for type 2 diabetes in the United States, with regulatory approval anticipated before 2026 concludes.
- In a separate announcement, Lilly disclosed that elevated Zepbound dosages surpassed Novo’s Wegovy HD in fresh weight management data.
- Individuals receiving Zepbound 15 mg experienced approximately 5% additional weight reduction compared to Wegovy HD recipients.
Eli Lilly has intensified its competitive positioning in the obesity and diabetes treatment market with fresh comparative analyses released this week. The pharmaceutical giant published clinical data directly contrasting its therapeutic offerings with competing products from Novo Nordisk.
The company announced Tuesday that Foundayo, its oral medication, demonstrates superior efficacy compared to Novo’s oral Ozempic formulation in adult patients managing type 2 diabetes. This assertion derives from an indirect comparative analysis rather than a direct head-to-head clinical trial.
The pharmaceutical company utilized findings from two distinct late-stage clinical investigations to establish this comparison. The analysis examined Foundayo’s 17.2 mg formulation against Novo’s 25 mg oral semaglutide tablet.
Based on Lilly’s findings, Foundayo produced up to 2% superior weight reduction compared to the higher-dose oral Ozempic formulation. The pharmaceutical company additionally documented marginally enhanced glycemic control within the identical evaluation.
The 25 mg oral Ozempic tablet currently lacks regulatory clearance in the United States for type 2 diabetes management. The Food and Drug Administration’s determination is anticipated before the conclusion of 2026.
Novo Nordisk Responds
Novo Nordisk promptly challenged the comparative analysis. A company representative informed Reuters that the research concentrated on individuals with type 2 diabetes rather than obesity as the primary condition.
This differentiation carries significant implications. Diabetes patients generally demonstrate reduced weight loss in clinical investigations compared to participants treated exclusively for obesity management.
Both the oral Ozempic tablet and Foundayo are classified within the GLP-1 receptor agonist therapeutic category. These medications function by modulating blood glucose levels and reducing appetite signals.
Comparing Zepbound and Wegovy HD
Lilly extended its competitive analysis beyond diabetes management. The corporation unveiled additional comparative findings between its injectable medication Zepbound and Novo’s high-dosage Wegovy formulation.
This evaluation encompassed Zepbound’s 10 mg and 15 mg formulations versus Wegovy HD throughout a 72-week treatment period. Both represent extensively prescribed injectable obesity medications.
Participants receiving Zepbound 15 mg demonstrated approximately 5% superior average body weight reduction compared with Wegovy HD recipients. Those administered the 10 mg formulation achieved roughly 3% additional weight loss.
According to Lilly’s analysis, individuals on the 15 mg dosage were three times more probable to achieve 20% or greater weight reduction compared to Wegovy HD participants. Treatment discontinuation rates attributed to adverse effects remained comparable across all treatment cohorts.
The comparative information originated from Lilly’s SURMOUNT-1 clinical trial and Novo’s STEP UP research programs. Both investigations recruited thousands of overweight or obese participants from multiple international locations.
Lilly disclosed these results at the European Association for the Study of Diabetes annual scientific conference. Rachel Batterham, serving as Lilly’s senior vice president of medical innovation, acknowledged that direct comparative trials provide optimal evidence, though indirect comparisons can deliver valuable insights when head-to-head studies remain unavailable.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
